{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.82","value":"2.0"},{"groupId":"OG001","spread":"0.55","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"To determine the average number of leukapheresis sessions required to collect 2.5 x10\\^6 CD34+ cells/kg.","dispersionType":"Standard Deviation","groups":[{"description":"Patients followed administration of TG-0054 (3.14 mg/kg) alone and leukapheresis start from study day 1.","id":"OG000","title":"TG-0054 (3.14 mg/kg)"},{"description":"Patients followed administration of TG-0054 (3.14 mg/kg) combined with granulocyte colony-stimulating factor (G-CSF) and leukapheresis start from study day 8.","id":"OG001","title":"TG-0054 (3.14 mg/kg)+G-CSF"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"1 week","title":"the Average Number of Leukapheresis Sessions","type":"SECONDARY","unitOfMeasure":"number of leukapheresis sessions"}